The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ILD with a granulomatous component
Hepatic granulomas also described. Sarcoidosis may also develop in virus C hepatitis unexposed to interferon
Publications
Occult interferon α-induced pulmonary granulomatosis despite continuation of treatment.
International journal of clinical pharmacology and therapeutics. 2014;52(11):1012-6
Sarcoidosis and hepatitis C: clinical description of 11 cases.
European journal of gastroenterology & hepatology. 2010;22(8):967-72
Pulmonary sarcoidosis induced by interferon-alpha therapy.
The American journal of surgical pathology. 2005;29(7):976-9
Ramos-Casals M, Mañá J, Nardi N, Brito-Zerón P, Xaubet A, Sánchez-Tapias JM, Cervera R, Font J, HISPAMEC Study Group
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.
Medicine. 2005;84(2):69-80
Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004;39(11):1724-9
Interferon-alpha therapy associated with the development of sarcoidosis.
Chest. 1999;116(2):569-72